We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From Oct 2019 to Oct 2024
Mylan NV received board approval to repurchase up to $1 billion of its shares, three days after losing its hostile bid for Perrigo Co.
The authorization expires Aug. 27, 2016.
Mylan Executive Chairman Robert Coury said the board's authorization "provides us with optimal flexibility and allows us to be opportunistic in repurchasing shares, thereby investing in Mylan's strong growth prospects and exciting future, which we continue to believe are substantially undervalued."
Mylan suffered defeat Friday in a landmark hostile takeover bid, dealing a blow to the generic-drug maker.
Perrigo shareholders rejected Mylan's $26 billion takeover offer, the companies said Friday. The outcome surprised many analysts and investors who predicted Mylan would eke out a victory in its pursuit of Dublin-based Perrigo, which principally makes store-brand versions of cold and allergy medicines.
Write to Anne Steele at Anne.Steele@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 16, 2015 12:35 ET (17:35 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
